Sunshine Biopharma Launches a New Generic Prescription Drug
Sunshine Biopharma (NASDAQ:SBFM) has launched Ursodiol, a new generic prescription drug, through its Canadian subsidiary Nora Pharma. Ursodiol, a generic version of URSO DS®, is used for managing cholestatic liver diseases and gallstone treatment. The global Ursodiol market, valued at $457.9 million in 2022, is projected to reach $933.9 million by 2029, with a 10.7% CAGR. This marks the company's third product launch this year in the Canadian generic drugs market, which is estimated at $9.7 billion in 2023 and expected to grow to $19.2 billion by 2032.
Sunshine Biopharma (NASDAQ:SBFM) ha lanciato Ursodiol, un nuovo farmaco generico da prescrizione, attraverso la sua controllata canadese Nora Pharma. Ursodiol, una versione generica di URSO DS®, è utilizzato per la gestione delle malattie epatiche colestatiche e per il trattamento dei calcoli biliari. Il mercato globale dell'Ursodiol, valutato a 457,9 milioni di dollari nel 2022, è proiettato a raggiungere 933,9 milioni di dollari entro il 2029, con un tasso di crescita annuo composto (CAGR) del 10,7%. Questo segna il terzo lancio di prodotto dell'azienda quest'anno nel mercato canadese dei farmaci generici, che è stimato a 9,7 miliardi di dollari nel 2023 e si prevede cresca fino a 19,2 miliardi di dollari entro il 2032.
Sunshine Biopharma (NASDAQ:SBFM) ha lanzado Ursodiol, un nuevo medicamento genérico bajo prescripción, a través de su filial canadiense Nora Pharma. Ursodiol, una versión genérica de URSO DS®, se utiliza para el manejo de enfermedades hepáticas colestáticas y para el tratamiento de cálculos biliares. El mercado global de Ursodiol, valorado en 457,9 millones de dólares en 2022, se proyecta que alcanzará los 933,9 millones de dólares para 2029, con una tasa de crecimiento anual compuesta (CAGR) del 10,7%. Este lanzamiento marca el tercer producto de la empresa este año en el mercado canadiense de medicamentos genéricos, que se estima en 9,7 mil millones de dólares en 2023 y se espera que crezca hasta 19,2 mil millones de dólares para 2032.
Sunshine Biopharma (NASDAQ:SBFM)는 캐나다 자회사인 Nora Pharma를 통해 Ursodiol, 새로운 일반 처방 약물을 출시했습니다. Ursodiol은 URSO DS®의 일반 버전으로, 담즙 정체성 간질환 관리 및 담석 치료에 사용됩니다. 글로벌 Ursodiol 시장은 2022년에 4억 5790만 달러로 평가되었으며, 2029년까지 9억 3390만 달러에 도달할 것으로 예상되며, 연평균 성장률(CAGR)은 10.7%입니다. 이는 올해 캐나다 일반 의약품 시장에서 회사의 세 번째 제품 출시에 해당하며, 이 시장은 2023년 97억 달러로 추정되며 2032년까지 192억 달러로 성장할 것으로 예상됩니다.
Sunshine Biopharma (NASDAQ:SBFM) a lancé Ursodiol, un nouveau médicament générique sur ordonnance, par le biais de sa filiale canadienne Nora Pharma. Ursodiol, une version générique d'URSO DS®, est utilisé pour gérer les maladies hépatiques cholestatiques et le traitement des calculs biliaires. Le marché mondial de l'Ursodiol, évalué à 457,9 millions de dollars en 2022, devrait atteindre 933,9 millions de dollars d'ici 2029, avec un taux de croissance annuel composé (CAGR) de 10,7%. Cela marque le troisième lancement de produit de l'entreprise cette année sur le marché canadien des médicaments génériques, qui est estimé à 9,7 milliards de dollars en 2023 et qui devrait atteindre 19,2 milliards de dollars d'ici 2032.
Sunshine Biopharma (NASDAQ:SBFM) hat Ursodiol, ein neues generisches Rezeptmedikament, über ihre kanadische Tochtergesellschaft Nora Pharma auf den Markt gebracht. Ursodiol, eine generische Version von URSO DS®, wird zur Behandlung von cholestatischen Lebererkrankungen und von Gallensteinen eingesetzt. Der globale Ursodiol-Markt, der 2022 auf 457,9 Millionen Dollar geschätzt wurde, wird voraussichtlich bis 2029 auf 933,9 Millionen Dollar anwachsen, mit einer jährlichen Wachstumsrate (CAGR) von 10,7%. Dies ist der dritte Produkteinführung des Unternehmens in diesem Jahr auf dem kanadischen Markt für Generika, der 2023 auf 9,7 Milliarden Dollar geschätzt wird und bis 2032 voraussichtlich auf 19,2 Milliarden Dollar wachsen wird.
- Launch of new generic drug Ursodiol in Canadian market
- Third product launch in 2023, showing consistent product expansion
- Target market (global Ursodiol) expected to grow from $457.9M to $933.9M by 2029
- Operating in Canadian generic drugs market projected to reach $19.2B by 2032
- None.
Insights
The launch of generic Ursodiol represents a strategic expansion in Sunshine Biopharma's portfolio. The timing is particularly favorable given the projected
The product's dual therapeutic applications - treating cholestatic liver diseases and managing gallstones - provide multiple revenue streams. Being the company's third product launch this year demonstrates effective execution of their growth strategy. However, investors should note that market penetration and revenue impact will depend on pricing strategy and competition from other generic manufacturers.
The Canadian generic drug market's projected growth to
For a micro-cap company with a market cap of just
FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched a new generic prescription drug.
The newly launched drug is Ursodiol, a generic version of URSO DS®. Ursodiol, also known as ursodeoxycholic acid (UDCA), is indicated for the management of cholestatic liver diseases, including primary biliary cirrhosis (PBC). Ursodiol is also used to (i) dissolve gallstones in people who do not want surgery or cannot have surgery to remove gallstones, or (ii) prevent the formation of gallstones in overweight people engaged in a rapid weight loss program. Nora Pharma's Ursodiol is available for the Canadian market in 250 mg and 500 mg tablets.
The market size of Ursodiol in Canada is part of the broader global Ursodiol market, which is projected to grow significantly. The global Ursodiol market was valued at approximately
"This is the third new product we have introduced this year. We continue to grow through the addition of new products to strengthen our presence in the Canadian generic drugs market which was estimated to be
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 63 generic prescription drugs on the market in Canada and 31 additional drugs scheduled to be launched in the remainder of 2024 and in 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy.
In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For Additional Information:
Sunshine Biopharma Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma, Inc.
View the original press release on accesswire.com
FAQ
What new drug did Sunshine Biopharma (SBFM) launch in November 2023?
What is the projected market size for Ursodiol by 2029?
How many new products has SBFM launched in 2023?
What are the medical uses of Ursodiol (SBFM's new drug)?
